AL
RGLS

Airain Ltd’s Regulus Therapeutics RGLS Stock Holding History

Airain Ltd’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-224
Closed -$186K – 856
2016
Q1 		$186K Sell
224
-32
-13% -$25.5K 0.01% 698
2015
Q4 		$268K Buy
+256
New +$257K 0.02% 647
2015
Q2 		– Sell
-244
Closed -$496K – 1052
2015
Q1 		$496K Buy
+244
New +$530K 0.03% 494

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Airain Ltd's RGLS Position: Q2 2016 in Review

Airain Ltd sold out of Regulus Therapeutics (RGLS) in Q2 2016, closing a stake of 224 shares — an estimated $186K sold.

Airain Ltd first reported a position in RGLS in Q1 2015 and held it in 3 quarters. The position peaked at $496K in Q1 2015. 83 funds tracked by Wall St. Rank hold RGLS as of Q2 2016.

  • Airain Ltd reported no remaining Regulus Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Airain Ltd sold 224 Regulus Therapeutics shares in Q2 2016, an estimated $186K.
  • Airain Ltd first reported a position in Regulus Therapeutics in Q1 2015 and held it in 3 quarters.
  • Airain Ltd's Regulus Therapeutics position peaked at $496K in Q1 2015.
  • 83 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2016.

Based on Airain Ltd's 13F filing for Q2 2016, filed 5 Aug 2016.